Sally Vanden-Hehir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sally Vanden-Hehir has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alison Nicola Hulme
University of Edinburgh
1 shared publication - Anna Williams
UK Dementia Research Institute at The University of Edinburgh, Edinburgh, UK
1 shared publication - Martin Lee
Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK
1 shared publication - Valerie G. Brunton
Edinburgh Cancer Research, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XR, UK
1 shared publication - William J. Tipping
Department of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, Glasgow, UK
1 shared publication
Latest Publications
- Open Access
- 3 March 2019
- Published by MDPI AG in Nanomaterials
- Vol. 9 (3) , 341
Raman Imaging of Nanocarriers for Drug Delivery
The efficacy of pharmaceutical agents can be greatly improved through nanocarrier delivery. Encapsulation of pharmaceutical agents into a nanocarrier can enhance their bioavailability and biocompatibility, whilst also facilitating targeted drug delivery to specific locations within the body. However, detailed understanding of the in vivo activity of the nanocarrier-drug conjugate is required prior to regulatory approval as a safe and effective treatment strategy. A comprehensive understanding of how nanocarriers travel to, and interact with, the intended target is required in order to optimize the dosing strategy, reduce potential off-target effects, and unwanted toxic effects. Raman spectroscopy has received much interest as a mechanism for label-free, non-invasive imaging of nanocarrier modes of action in vivo. Advanced Raman imaging techniques, including coherent anti-Stokes Raman scattering (CARS) and stimulated Raman scattering (SRS), are paving the way for rigorous evaluation of nanocarrier activity at the single-cell level. This review focuses on the development of Raman imaging techniques to study organic nanocarrier delivery in cells and tissues.
- 3 March 2019
- Published by MDPI AG in Nanomaterials
- Vol. 9 (3) , 341
Open AccessRaman Imaging of Nanocarriers for Drug Delivery
The efficacy of pharmaceutical agents can be greatly improved through nanocarrier delivery. Encapsulation of pharmaceutical agents into a nanocarrier can enhance their bioavailability and biocompatibility, whilst also facilitating targeted drug delivery to specific locations within the body. However, detailed understanding of the in vivo activity of the nanocarrier-drug conjugate is required prior to regulatory approval as a safe and effective treatment strategy. A comprehensive understanding of how nanocarriers travel to, and interact with, the intended target is required in order to optimize the dosing strategy, reduce potential off-target effects, and unwanted toxic effects. Raman spectroscopy has received much interest as a mechanism for label-free, non-invasive imaging of nanocarrier modes of action in vivo. Advanced Raman imaging techniques, including coherent anti-Stokes Raman scattering (CARS) and stimulated Raman scattering (SRS), are paving the way for rigorous evaluation of nanocarrier activity at the single-cell level. This review focuses on the development of Raman imaging techniques to study organic nanocarrier delivery in cells and tissues.